source
- Bausch + Lomb and Celldex rocked by respective phase 2 flopsBausch + Lomb and Celldex have independently reported phase 2 flops. While Celldex ended work in the indication in response to the setback, Bausch + Lomb noted numerical improvements and explorator…Fierce Biotech · 8h ago↗ source
- FDA approves Regeneron's first siRNA therapy for generalized myasthenia gravisThe FDA has granted approval for Regeneron's siRNA drug Livsayis (cemdisiran) for adult patients with generalized myasthenia gravis who are positive for anti‑acetylcholine receptor antibodies. Thi…